ReviewBlood2021
How I treat microangiopathic hemolytic anemia in patients with cancer.
Review in Blood, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Ocular manifestations of primary thrombotic microangiopathies : a descriptive systematic review.BMC ophthalmology · 2025Pooled it
- Microangiopathic Hemolytic Anemia Is a Late and Fatal Complication of Gastric Signet Ring Cell Carcinoma: A Systematic Review and Case-Control Study.The oncologist · 2022Pooled it
- Cancer-Related Microangiopathic Haemolytic Anemia Revealing Occult Metastatic Gastrointestinal Signet-Ring Cell Carcinoma: A Clinicopathological Case Report and Practical Differential Diagnostic Approach.Clinical case reports · 2026Article
- An Unusual Case of Thrombocytopenia and Renal Failure Revealing Malignancy-Associated Thrombotic Microangiopathy.Cureus · 2026Article
- Article
- Thrombotic thrombocytopenic purpura as a complication of pembrolizumab: a case report and literature Review.Annals of hematology · 2026Review
- A case of immune thrombocytopenia aggravated by therapy for hypercortisolism in adrenocortical carcinoma.Therapeutic advances in endocrinology and metabolism · 2026Article
- Case Report: Sintilimab-associated acute interstitial nephritis in a patient with severe thrombocytopenia: clinical diagnosis and treatment strategy when renal biopsy is contraindicated.Frontiers in medicine · 2026Article
- Cancer-related microangiopathic hemolytic anemia (CR-MAHA) in a metastatic breast cancer patient with a germ-line ATM single nucleotide variant and an ESR1 fusion variant: insights from a case report on early diagnosis and improved outcomes.Frontiers in oncology · 2026Article
- Efficacy of Plasma Exchange in Secondary Thrombotic Microangiopathy: A Case Report and Literature Review.Cureus · 2026Article
- Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Low Breast Cancer With Cancer-Related Microangiopathic Hemolytic Anemia: A Case Report.Cancer innovation · 2025Article
- Linking preclinical models to clinical realities: VEGF/VEGFR inhibitors and thrombotic microangiopathy in cancer therapy.iMetaOmics · 2025Article
- Metastatic Adenocarcinoma to Bone Marrow Presenting as Microangiopathic Hemolytic Anemia - Diagnostic Issues in a Series of Seven Young Adults.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Article
- Microangiopathic Hemolytic Anemia as paraneoplastic syndrome secondary to Pheochromocytoma: a rare case report.Oxford medical case reports · 2025Article
- A real-world pharmacovigilance analysis of hepatitis B vaccine using the U.S. Vaccine Adverse Event Reporting System (VAERS) database.Scientific reports · 2025Article
- Thrombocytopenia in Critically Ill Children: A Review for Practicing Clinicians.Children (Basel, Switzerland) · 2025Review
- Article
- Galangin Triggers Eryptosis and Hemolysis Through CaInternational journal of molecular sciences · 2024Article
- Article
- Clinical Characteristics and Treatment Courses of Trauma-Induced Thrombotic Microangiopathy: A Retrospective Study.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Microangiopathic hemolytic anemia (MAHA) with thrombocytopenia, suggests a thrombotic microangiopathy (TMA), linked with thrombus formation affecting small or larger vessels. In cancer patients, it may be directly related to the underlying malignancy (initial presentation or progressive disease), to its treatment, or a separate incidental diagnosis. It is vital to differentiate incidental thrombotic thrombocytopenia purpura or atypical hemolytic uremic syndrome in cancer patients presenting with a TMA, as they have different treatment strategies, and prompt initiation of treatment impacts outcome. In the oncology patient, widespread microvascular metastases or extensive bone marrow involvement can cause MAHA and thrombocytopenia. A disseminated intravascular coagulation (DIC) picture may be precipitated by sepsis or driven by the cancer itself. Cancer therapies may cause a TMA, either dose-dependent toxicity, or an idiosyncratic immune-mediated reaction due to drug-dependent antibodies. Many causes of TMA seen in the oncology patient do not respond to plasma exchange and, where feasible, treatment of the underlying malignancy is important in controlling both cancer-TMA or DIC driven disease. Drug-induced TMA should be considered and any putative causal agent stopped. We will discuss the differential diagnosis and treatment of MAHA in patients with cancer using clinical cases to highlight management principles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.